Dr. Bianchi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
75 Francis St
Boston, MA 02115Phone+1 617-732-5190Fax+1 617-732-5706- Is this information wrong?
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2012 - 2016
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2009 - 2012
Universita San RaffaeleClass of 2006
Certifications & Licensure
MA State Medical License 2012 - 2025
MN State Medical License 2011 - 2012
Publications & Presentations
PubMed
- Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.Annamaria Gulla, Eugenio Morelli, Megan Johnstone, Marcello Turi, Mehmet K Samur, Cirino Botta, Selma Cifric, Pietro Folino, Delaney Vinaixa, Francesca Barello, Cole C...> ;Blood. 2024 Mar 29
- 1 citationsQuantification of Right Ventricular Amyloid Burden with 18F-florbetapir PET/CT and its Association with Right Ventricular Dysfunction and Outcomes in Light-Chain Amylo...Datar, Y., Clerc, O., Cuddy, S., Kim, S., Taylor, A., Neri, J., Benz, D., Bianchi, G., Yee, A., Sanchorawala, V., Ruberg, F., Landau, H., Liao, R., Kijewski, M., Jeros...> ;European Heart Journal. Cardiovascular Imaging. 2024 Jan 9
- A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma.Shonali Midha, Monique A Hartley-Brown, Clifton C Mo, Shahrier Hossain, Omar Nadeem, Elizabeth K O'Donnell, Giada Bianchi, Adam S Sperling, Jacob P Laubach, Paul G Ric...> ;Expert Opinion on Drug Safety. 2023 Nov 28
- Join now to see all
Abstracts/Posters
- Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple MyelomaGiada Bianchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple MyelomaGiada Bianchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple MyelomaGiada Bianchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
The Economic Effects of the Coronavirus May Kill More Americans Than the Virus ItselfJanuary 25th, 2021- Administered Earlier, Cilta-Cel CAR T Produces Deep, Durable Responses in Multiple Myeloma PatientsDecember 9th, 2023
Hospital Affiliations
Dana-Farber Cancer InstituteBoston, Massachusetts
Brigham and Women's HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
